Keyphrases
177Lu-DOTATATE
100%
Lung Neuroendocrine Tumors
100%
68Ga-DOTATATE PET-CT
83%
Overall Survival
66%
Response Evaluation Criteria in Solid Tumors (RECIST)
50%
Progression-free Survival
33%
Chemotherapy
33%
Partial Response
33%
Stable Disease
33%
Atypical Carcinoid
33%
Typical Carcinoid
33%
Response Categories
33%
Somatostatin Receptor Expression
33%
Hazard Ratio
16%
Cumulative Activity
16%
Adverse Events
16%
Median Progression-free Survival
16%
Retrospective Review
16%
Leukemia
16%
Somatostatin Receptor
16%
Kaplan-Meier Analysis
16%
Common Terminology Criteria for Adverse Events (CTCAE)
16%
Measurable Disease
16%
Treatment-related Adverse Events
16%
Progressive Disease
16%
Myelodysplasia
16%
Assessment Method
16%
Lymphopenia
16%
Disease Control Rate
16%
Everolimus
16%
Log-rank Test
16%
Response Assessment
16%
Center of Excellence
16%
Radiosensitization
16%
4-cycle
16%
RECIST 1.1
16%
No Response
16%
Somatostatin Analogs
16%
Krenning Score
16%
ENet
16%
Medicine and Dentistry
Neuroendocrine Tumor
100%
Lutetium 177
100%
Lung
100%
Positron Emission Tomography-Computed Tomography
83%
Gallium 68
83%
Overall Survival
66%
Carcinoid
66%
Diseases
66%
Adverse Event
50%
Progression Free Survival
50%
Somatostatin Receptor
50%
Receptor Expression
33%
Hazard Ratio
16%
Myelodysplastic Syndrome
16%
Morphology
16%
Kaplan Meier Method
16%
Progressive Disease
16%
Leukemia
16%
Lymphocytopenia
16%
Log Rank Test
16%
Everolimus
16%
Somatostatin Derivative
16%
Pharmacology, Toxicology and Pharmaceutical Science
Neuroendocrine Tumor
100%
Lutetium 177
100%
Gallium 68
83%
Polyethylene Terephthalate
83%
Diseases
83%
Overall Survival
66%
Carcinoid
66%
Progression Free Survival
50%
Adverse Event
50%
Somatostatin Receptor
50%
Chemotherapy
33%
Leukemia
16%
Myelodysplastic Syndrome
16%
Everolimus
16%
Lymphocytopenia
16%
Somatostatin Derivative
16%
Agricultural and Biological Sciences
Polyethylene Terephthalate
100%
Lung
100%
Somatostatin Receptor
60%
Pretreatment
20%
Somatostatin
20%